Chemoradiotherapy vs chemotherapy as adjuvant treatment for localized gastric cancer: A propensity score-matched analysis
BMC Cancer Apr 11, 2018
Girardi DM, et al. - Overall survival (OS) benefits with chemoradiation (CRT) vs chemotherapy (CT) were determined when administered as adjuvant treatment for patients with localized gastric cancer (LGC) treated at Instituto do Cancer do Estado de Sao Paulo (ICESP) from 2012 to 2015. CRT was based on the INT-0116 regimen and CT consisted of a platinum and fluoropyrimidine doublet. A median follow-up of 23.5 months (CRT) and 20.6 months (CT) revealed no difference in OS between groups. In CRT and CT groups, the following were reported as the most prevalent grade 3/4 toxicities: nausea/vomiting (9.25 vs 4.9%), fatigue (9.3% vs 2.4%), mucositis (4.4% vs 1.2%), neutropenia (37.8% vs 20.9%), febrile neutropenia (3.9% vs 0%), anemia (4.3% vs 6.1%), thrombocytopenia (2.6% vs 4.9%), neuropathy (0 vs 2.4%) and hand-foot syndrome (0.4% vs 2.4%). Overall, similar efficacy, as well as tolerability of CT and CRT, was shown when given as adjuvant treatment for LGC.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries